Cite

Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related <scp> RAS </scp> and <scp> BRAF </scp> mutation status

MLA

Dorte Linnemann, et al. “Cetuximab plus Irinotecan Administered Biweekly with Reduced Infusion Time to Heavily Pretreated Patients with Metastatic Colorectal Cancer and Related RAS and BRAF Mutation Status.” International Journal of Cancer, vol. 148, Dec. 2020, pp. 2542–56. EBSCOhost, https://doi.org/10.1002/ijc.33448.



APA

Dorte Linnemann, Julia S. Johansen, Kristin Skougaard, Dorte Nielsen, Jakob V. Schou, Mette Karen Yilmaz, Per Pfeiffer, Finn Ole Larsen, Benny V. Jensen, Estrid Høgdall, & Helle Hjorth Johannesen. (2020). Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. International Journal of Cancer, 148, 2542–2556. https://doi.org/10.1002/ijc.33448



Chicago

Dorte Linnemann, Julia S. Johansen, Kristin Skougaard, Dorte Nielsen, Jakob V. Schou, Mette Karen Yilmaz, Per Pfeiffer, et al. 2020. “Cetuximab plus Irinotecan Administered Biweekly with Reduced Infusion Time to Heavily Pretreated Patients with Metastatic Colorectal Cancer and Related RAS and BRAF Mutation Status.” International Journal of Cancer 148 (December): 2542–56. doi:10.1002/ijc.33448.